Engage in sexual activity at any time with confidence!
Dong-A ST launched ‘Zydena 75mg,’ a one-tablet-per-day treatment designed to liberate users from worries over erectile dysfunction

-Enables users to engage in sexual activity confidently at any time
-Offers a broader choice to both doctors and patients

On December 12, 2013, Dong-A ST (President Park Chan-il) launched Zydena 75mg, a tablet which patients can take on a daily basis to cure their erectile dysfunction, instead of submitting to temporary on-the-spot medical treatment. The new product was launched as a follow-up measure to an earlier product, Zydena 50mg.

Now, Zydena, the pure brainchild of Dong-A, is available in a product lineup comprising four types of medical treatment for erectile dysfunction, including 50mg or 75mg daily or 100mg or 200mg on demand, depending on the patient’s physical conditions and needs.

This daily treatment is a new concept in the treatment of erectile dysfunction: Patients need no longer worry about their dysfunction and can engage in sexual activity at any time. All they have to do is take a tablet a day. Compared to traditional on-demand treatments which require careful planning each time a patient anticipates having sexual relations, this daily dosage enables them to engage in sexual relations without being conscious of their dysfunction at all.

As the latest product to be launched, Zydena 75mg showed an impressive rate of erectile improvement (83.5%) in the GAQ (Global Assessment Question) and a 95.4% improvement in a long-term stability clinical trial. In the Erectile Function Domain of the International Index of Erectile Function (IEEF), 47% of patients (about one in two persons) recovered their normal erectile function by the 24th week. Furthermore, a notable improvement was shown in terms of vaginal penetration, successful intercourse, and sexual satisfaction compared to placebos.

According to the IMS data, daily erectile dysfunction drugs accounted for 13.1% of the market share in Korea during the first three quarters of 2013, i.e. 8.8 billion won out of 67 billion won for all types of erectile dysfunction medicines. Since 2009, the year in which the first daily treatment drug was launched in Korea, share of the market has continued to rise. Compared to on-demand medical treatment, daily prescription shows fewer side effects in addition to freeing patients from serious concerns about when to take the medicine and how long its efficacy will last. As such, continuous market growth is anticipated for the new daily medication.

“We have launched Zydena 75mg in line with increasing demand and ongoing changes in the market trends. With the launch of Zydena 75mg, Dong-A has now become the only supplier in the country to offer two types of daily medication for erectile dysfunction,” said a marketing official of Dong-A ST. “Dong-A is hopeful that the launch of the 75mg medication will broaden choices for both doctors and patients and improve the quality of life for a large number of citizens who are concerned about their sex lives.”

Meanwhile, Zydena 75mg comes in two types of packages ？ packs of 4 tablets in addition to the 30-tablet packs - out of consideration for users with a restricted budget.